Does Sharp Health Plan Cover Eliquis?

How Sharp Health Plan Typically Covers Eliquis

Sharp Health Plan, based in San Diego, operates HMO, PPO, Medicare Advantage, and Covered California exchange plans. Most Sharp formularies include Eliquis, though the tier placement varies by plan year and product line.

On commercial HMO and PPO plans, Eliquis typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 3 placement generally means a fixed copay between $50 and $75 per 30-day fill, while Tier 4 may involve coinsurance of 25% to 40% of the drug's cost. Sharp Medicare Advantage plans follow CMS formulary guidelines and often place Eliquis on the brand specialty tier, where cost-sharing during the initial coverage phase can reach $90 or more per month before catastrophic coverage kicks in 1.

The only way to confirm your exact coverage is to check Sharp's online formulary search tool or call the member services number on the back of your insurance card. Formulary placement can shift during annual plan renewals, so a tier assignment from last year may not apply today.

What Eliquis Treats and Why Physicians Prescribe It

Eliquis (apixaban) is a factor Xa inhibitor that blocks a specific clotting protein in the blood. The FDA approved apixaban in December 2012 for stroke prevention in patients with non-valvular atrial fibrillation (AF). It later gained approvals for deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment, recurrence reduction, and post-surgical VTE prophylaxis after hip or knee replacement 2.

In the ARISTOTLE trial (N=18,201), apixaban 5 mg twice daily reduced stroke and systemic embolism by 21% compared with warfarin (HR 0.79 to 95% CI 0.66-0.95), with a 31% lower rate of major bleeding (HR 0.69 to 95% CI 0.60-0.80) 3. This trial established apixaban as one of the safest DOACs for AF patients, and the 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation gives DOACs a Class I recommendation over warfarin for eligible patients with non-valvular AF 4.

For VTE treatment, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional enoxaparin-warfarin therapy for recurrent VTE (RR 0.84 to 95% CI 0.60-1.18) and caused 69% less major bleeding (RR 0.31 to 95% CI 0.17-0.55) 5. That bleeding advantage is a primary reason cardiologists and hematologists favor Eliquis over older anticoagulants.

Understanding Your Out-of-Pocket Cost with Sharp

Your actual cost depends on three variables: your plan's tier placement for Eliquis, your deductible status, and whether you use the manufacturer's copay assistance program.

Without any assistance, a 30-day supply of brand-name Eliquis carries a wholesale acquisition cost of roughly $594, though retail pharmacy prices in the San Diego area often exceed $650 6. Sharp HMO members with a Tier 3 copay might pay $50 to $75 per fill. Sharp PPO members whose plan applies coinsurance rather than a flat copay could face $150 to $250 per month until reaching their out-of-pocket maximum.

Bristol-Myers Squibb and Pfizer offer a copay savings card for commercially insured patients that can reduce the copay to as little as $10 per month, with a maximum annual benefit. This card does not apply to government-funded plans, including Medicare Part D, Medicaid, or TRICARE. Sharp Medicare Advantage enrollees cannot use the manufacturer card but may qualify for the federal Extra Help (Low-Income Subsidy) program if their income falls below 150% of the federal poverty level 7.

A cost comparison table showing out-of-pocket ranges across Sharp plan types (HMO, PPO, Medicare Advantage, Covered California) with and without manufacturer assistance would go here after editorial review.

Prior Authorization and Step Therapy Requirements

Some Sharp Health Plan products require prior authorization (PA) before covering Eliquis. PA is more common on Medicare Advantage and Covered California plans than on employer-sponsored commercial plans. When PA is required, your prescribing physician must submit clinical documentation showing that the drug is medically necessary for an FDA-approved or guideline-supported indication.

Common PA criteria for DOACs include a confirmed diagnosis of atrial fibrillation (by ECG or cardiac monitoring), a CHA2DS2-VASc score of 2 or higher in men or 3 or higher in women, and documentation that the patient has adequate renal function for the prescribed dose 4. For VTE indications, Sharp may request imaging confirmation (ultrasound or CT pulmonary angiography) and a treatment duration plan.

Step therapy is less common for Eliquis than for some other brand medications, but certain Sharp plans may require trial of warfarin first. If your physician believes warfarin is clinically inappropriate (due to dietary interaction risk, INR monitoring burden, or documented labile INR), they can submit a step therapy exception request. The Endocrine Society and AHA guidelines both support DOAC-first approaches in most AF and VTE patients, which strengthens exception requests 8.

How to Verify Your Specific Sharp Health Plan Coverage

Formularies change annually. The steps below will get you a definitive answer within 24 hours.

Step 1: Check the online formulary. Visit Sharp Health Plan's website, manage to the "Find a Drug" or formulary search page, and enter "apixaban" or "Eliquis." The result will show the tier, any quantity limits, and PA requirements for your specific plan ID.

Step 2: Call member services. The number on your Sharp ID card connects you to a benefits specialist who can confirm coverage details, including whether your deductible has been met and what your exact copay or coinsurance will be.

Step 3: Ask your pharmacist to run a test claim. A Sharp-contracted pharmacy can submit a test adjudication to see exactly what the plan will pay and what your cost-share is. This takes about five minutes at the pharmacy counter.

Step 4: Request a coverage determination in writing. If you want a formal, written confirmation (useful before starting a long-term medication), you can request a coverage determination from Sharp within 72 hours for standard requests or 24 hours for expedited requests involving urgent clinical need.

What Happens If Sharp Denies Coverage

A denial does not always mean you cannot get Eliquis through your Sharp plan. The appeals process has multiple levels, and denials are overturned frequently when clinical documentation supports the prescription.

Sharp Health Plan follows California Department of Managed Health Care (DMHC) appeal timelines. You have 180 days from the denial date to file an internal appeal. Sharp must respond within 30 calendar days for standard appeals or 72 hours for urgent cases. If the internal appeal is denied, you can escalate to an Independent Medical Review (IMR) through the DMHC at no cost 9.

Your physician's letter of medical necessity should include the specific diagnosis, relevant guideline citations (such as the 2019 AHA/ACC AF guidelines recommending DOACs over warfarin), any contraindications to alternative therapies, and the clinical consequences of not receiving the prescribed medication.

Dr. Gregory Lip, a professor of cardiovascular medicine at the University of Liverpool, has stated: "For the majority of patients with atrial fibrillation, direct oral anticoagulants represent the standard of care. Barriers to DOAC access can lead to suboptimal stroke prevention and increased hemorrhagic risk from older agents" 10.

Alternatives If Eliquis Is Not Covered or Too Expensive

If your Sharp plan does not cover Eliquis at an affordable tier, several alternatives exist. Each has a different safety and efficacy profile.

Xarelto (rivarelbana). Another factor Xa inhibitor, taken once daily for AF (vs. twice daily for Eliquis). The ROCKET AF trial (N=14,264) showed non-inferiority to warfarin for stroke prevention, though gastrointestinal bleeding rates were higher than with apixaban 11.

Warfarin. The oldest oral anticoagulant, available as a low-cost generic ($4 to $15 per month). Requires regular INR monitoring every 2 to 4 weeks and has significant food and drug interactions. The ARISTOTLE trial showed apixaban had superior efficacy and safety compared with warfarin, but warfarin remains a reasonable choice when cost is the primary barrier and the patient can maintain stable INR values 3.

Savaysa (edoxaban). A once-daily factor Xa inhibitor studied in the ENGAGE AF-TIMI 48 trial (N=21,105). It showed non-inferiority to warfarin for stroke prevention and lower bleeding rates, but it requires CrCl between 15 and 95 mL/min (it is less effective at higher kidney function levels) 12.

Pradaxa (dabigatran). A direct thrombin inhibitor, the first DOAC approved in the United States. The RE-LY trial (N=18,113) demonstrated the 150 mg dose was superior to warfarin for stroke prevention but had higher GI bleeding rates 13. Dabigatran has a specific reversal agent (idarucizumab), which may matter for surgical patients.

The American College of Cardiology recommends discussing efficacy, bleeding risk, renal function, dosing convenience, and cost when choosing among DOACs, rather than defaulting to any single agent 4.

The Generic Apixaban Timeline

No generic version of apixaban has reached the U.S. market as of May 2026. Bristol-Myers Squibb and Pfizer hold patents on Eliquis that have been the subject of extensive litigation. Multiple generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA, and patent expiration dates have been contested in court 6.

When a generic does become available, prices typically drop 80% to 85% within the first year of multi-source generic competition, based on FDA and FTC analyses of historical generic entry patterns 14. For Sharp Health Plan members, a generic apixaban would likely be placed on Tier 1 or Tier 2, with copays as low as $5 to $20 per month.

Until then, the manufacturer copay card, patient assistance programs (Bristol-Myers Squibb Patient Assistance Foundation), and pharmacy discount programs like those from GoodRx remain the primary tools for reducing out-of-pocket costs on brand-name Eliquis.

Dosing and Safety Considerations

The standard Eliquis dose for AF is 5 mg twice daily. A reduced dose of 2.5 mg twice daily applies to patients meeting at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher 2. For VTE treatment, the initial dose is 10 mg twice daily for 7 days, followed by 5 mg twice daily for at least 3 months.

The 2023 CHEST guideline update on antithrombotic therapy recommends DOACs over warfarin for VTE treatment in patients without active cancer or antiphospholipid syndrome 15. Dr. Clive Kearon, a lead author on the CHEST VTE guidelines, noted: "The simplicity, safety profile, and lack of monitoring requirements for DOACs make them the default first-line agents for most patients with venous thromboembolism."

Sharp-contracted physicians in the San Diego area can prescribe Eliquis through the plan's pharmacy network. Patients should confirm their preferred pharmacy is in-network, as out-of-network pharmacies may result in higher cost-sharing or no coverage at all. Sharp Health Plan's mail-order pharmacy option often provides a 90-day supply at a lower per-unit cost than retail 30-day fills.

Patients taking Eliquis should not discontinue the medication without consulting their physician. Abrupt discontinuation of anticoagulant therapy increases thromboembolic risk, and the FDA label carries a boxed warning about this risk in AF patients 2.